A Phase 3 interventional study of Durvalumab and Cisplatin in Locally Advanced Cervical Cancer, sponsored by AstraZeneca. Completed at 117 sites in 15 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-07-26.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Uterine Cervical Neoplasms by AstraZeneca — 3 open to participants now, 5 under way, 1 of them phase 3. Uterine Cervical Neoplasms · AstraZeneca.
Among the 11 studies in Uterine Cervical Neoplasms by AstraZeneca, this one is one of 2 that started in 2019, is one of 2 in phase 3, and was the 3rd registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →3 of the 11 studies in Uterine Cervical Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States
Ages 18–130
AstraZeneca · Sites in United States, Australia, Brazil and 9 more countries
Ages 18+
AstraZeneca · Sites in United States, Brazil, Canada and 16 more countries
Ages 15+ · Women only
By country, each count listing its studies:
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 2
First in 2010; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 770 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 257 across the 9 interventional studies, 120 across the 2 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
2 of the studies in Uterine Cervical Neoplasms by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Uterine Cervical Neoplasms by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer
Women will be randomized in a 1:1 ratio to receive treatment with concurrent durvalumab + standard of care (SoC) or Placebo + Soc, followed by durvalumab/placebo maintenance for 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For inclusion in the study, patients should fulfill the following criteria:
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
durvalumab + standard of care concurrent chemoradiation therapy(SoC CCRT) followed by durvalumab monotherapy up to 24 months or until PD from the date of randomization
Biological: Durvalumab · Drug: Cisplatin · Drug: Carboplatin · Radiation: external beam radiation therapy (EBRT) + brachytherapy
placebo + standard of care concurrent chemoradiation therapy(SoC CCRT)
Drug: Cisplatin · Drug: Carboplatin · Radiation: external beam radiation therapy (EBRT) + brachytherapy
IV infusion every 4 weeks
Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Radiation therapy per standard of care
Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression
PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression
Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression, PD-L1 Expression >= 1%
PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression
Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Overall Survival (Count)
Number of Participants with Overall Survival (OS) where OS was defined as the time from the date of randomisation until death by any cause
Time frame: Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months
Overall Survival (Duration)
Time from the date of randomisation until death by any cause
Time frame: Time from date of randomisation until date of death by any cause, assessed up to the data cut-off date (3rd July 2023), assessed up to a maximum of 51.7 months
Objective Response Rate (ORR)
Percentage of evaluable patients with an Investigator-assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target and non-target lesions and no new lesions. PR defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion
Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Complete Response Rate
Percentage of evaluable patients with an overall visit response of Complete Response (disappearance of all target and non-target lesions)
Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Duration of Response (DoR) in Patients With Complete Response (CR)
Time from date of first documented CR until date of documented progression or death in the absence of progression. For patients who did not progress their DoR was their Progression-free survival censoring time
Time frame: Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
| Milestone | Durvalumab + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| Started | 385 | 385 |
| Completed | 268 | 249 |
| Not completed | 117 | 136 |
| Withdrew: Death | 90 | 111 |
| Withdrew: Lost to follow-up | 7 | 7 |
| Withdrew: Withdrawal by subject | 19 | 16 |
| Withdrew: No longer eligible due to additional cancer diagnosis | 0 | 1 |
| Withdrew: Other | 1 | 1 |
PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression
| Months | Durvalumab + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression | NA (NA to NA) | NA (NA to NA) |
PFS defined as time from date of randomisation until date of tumour progression or death by any cause, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression
| Months | Durvalumab + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression, PD-L1 Expression >= 1% | NA (NA to NA) | NA (26.9 to NA) |
Number of Participants with Overall Survival (OS) where OS was defined as the time from the date of randomisation until death by any cause
| Participants | Durvalumab + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| Died | 91 | 112 |
| Censored (includes subjects who withdrew consent and subjects who were lost to follow up) | 294 | 273 |
Time from the date of randomisation until death by any cause
| Months | Durvalumab + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| Overall Survival (Duration) | NA (NA to NA) | NA (NA to NA) |
Percentage of evaluable patients with an Investigator-assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target and non-target lesions and no new lesions. PR defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion
| Percentage of Participants | Durvalumab + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| Objective Response Rate (ORR) | 82.6 | 80.5 |
Percentage of evaluable patients with an overall visit response of Complete Response (disappearance of all target and non-target lesions)
| Percentage of Participants | Durvalumab + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| Complete Response Rate | 42.9 | 40.3 |
Time from date of first documented CR until date of documented progression or death in the absence of progression. For patients who did not progress their DoR was their Progression-free survival censoring time
| Months | Durvalumab + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| Duration of Response (DoR) in Patients With Complete Response (CR) | NA (NA to NA) | NA (NA to NA) |
Collected over From the time of signature of informed consent throughout the treatment period (median duration of 656 and 532 days for durvalumab and placebo respectively) up to and including the 90-day safety follow-up period following the last dose of study treatment, up to a maximum of 53 months (Data cut-off date of 03Jul2023). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durva + SoC CCRT | 91/385 (23.6%) | 113/385 (29.4%) | 373/385 (96.9%) |
| Placebo + SoC CCRT | 112/385 (29.1%) | 90/384 (23.4%) | 368/384 (95.8%) |
| Event | Durva + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 20/385 | 20/384 |
| Urinary tract infectionInfections and infestations | 16/385 | 11/384 |
| Vaginal haemorrhageReproductive system and breast disorders | 7/385 | 5/384 |
| Acute kidney injuryRenal and urinary disorders | 6/385 | 3/384 |
| Abdominal painGastrointestinal disorders | 6/385 | 2/384 |
| Radiation proctitisInjury, poisoning and procedural complications | 6/385 | 2/384 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/385 | 1/384 |
| HypokalaemiaMetabolism and nutrition disorders | 1/385 | 4/384 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/385 | 4/384 |
| PneumoniaInfections and infestations | 1/385 | 4/384 |
| Event | Durva + SoC CCRT | Placebo + SoC CCRT |
|---|---|---|
| NauseaGastrointestinal disorders | 213/385 | 202/384 |
| AnaemiaBlood and lymphatic system disorders | 209/385 | 200/384 |
| DiarrhoeaGastrointestinal disorders | 177/385 | 190/384 |
| VomitingGastrointestinal disorders | 105/385 | 107/384 |
| ConstipationGastrointestinal disorders | 97/385 | 87/384 |
| Urinary tract infectionInfections and infestations | 90/385 | 92/384 |
| Decreased appetiteMetabolism and nutrition disorders | 89/385 | 64/384 |
| Neutrophil count decreasedInvestigations | 74/385 | 85/384 |
| White blood cell count decreasedInvestigations | 71/385 | 85/384 |
| NeutropeniaBlood and lymphatic system disorders | 74/385 | 55/384 |
| Age, Continuous(Years) | Durvalumab + SoC CCRT | Placebo + SoC CCRT | Total |
|---|---|---|---|
| Mean | 49.6 ± 11.74 | 48.8 ± 11.67 | 49.2 ± 11.70 |
| Sex: Female, Male(Participants) | Durvalumab + SoC CCRT | Placebo + SoC CCRT | Total |
|---|---|---|---|
| Female | 385 | 385 | 770 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Durvalumab + SoC CCRT | Placebo + SoC CCRT | Total |
|---|---|---|---|
| White | 130 | 125 | 255 |
| Black or African American | 10 | 12 | 22 |
| Asian | 152 | 148 | 300 |
| American Indian or Alaska Native | 47 | 56 | 103 |
| Other | 46 | 44 | 90 |
Showing the first 100 of 117 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2019 to primary completion in Jan 2022, 35 months.
Results were first posted in Mar 2023, 1 year 1 month after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 35 months is close to that.
Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab